Nemolizumab clinical trials
How each study uses nemolizumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the nemolizumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 12 Aug 2024 · NEMLUVIO · BLA 761390 (FDA, Drugs@FDA)
- European Union
- 12 Feb 2025 · Nemluvio · EMEA/H/C/006149 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
26 studies that test it; most in 2026 (7)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2017 | 2 |
| 2019 | 4 |
| 2020 | 3 |
| 2021 | 3 |
| 2022 | 4 |
| 2023 | 1 |
| 2025 | 1 |
| 2026 | 7 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 23 · Other 3
Galderma R&D (20) · Maruho Co., Ltd. (1) · Chugai Pharmaceutical (1) · Mayo Clinic (1) · University of Texas Southwestern Medical Center (1) · University of California, San Francisco (1) · The Skin Center Dermatology Group (1)
Often tested with
Tested in the same studies.
Triamcinolone (1) · Fluorouracil (1) · Calcipotriene (1) · Tapinarof (1) · Crisaborole (1) · Tacrolimus (1) · Adalimumab (1) · Etanercept (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4, 1 in phase 3
Studies that test nemolizumab, phase 3 first.
- Oct 2027Randomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Subjects With Moderate-to-severe Atopic DermatitisPhase 3 · Galderma R&D
- Dec 2026Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)Phase 2 · Galderma R&D
- Jun 2027Nemolizumab to Treat Lichen Planopilaris, a Noncontrolled, Prospective, Pilot Study.Phase 4 · The Skin Center Dermatology Group
- Sep 2027Nemolizumab for LSPhase 2 · University of Texas Southwestern Medical Center
Studies
Open first, then newest update. How each study uses nemolizumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 26
- Randomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Subjects With Moderate-to-severe Atopic DermatitisRecruitingPhase 3Galderma R&DNCT07762833Written as Nemolizumab 30 mg
- Nemolizumab for the Treatment of Moderate to Severe Chronic Hepatic PruritusNot yet recruitingPhase 2Mayo ClinicNCT07843420Written as Nemolizumab-ilto
- Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants Aged 6 to 23 Months With Moderate-to Severe Atopic DermatitisRecruitingPhase 2Galderma R&DNCT07660835Written as Nemolizumab
- Nemolizumab for LSNot yet recruitingPhase 2University of Texas Southwestern Medical CenterNCT07704775Written as Nemolizumab 30 mg
- Utilization of a Microdevice for Psoriasis and Atopic DermatitisNot yet recruitingPhase 4University of California, San FranciscoNCT07352566Written as Nemolizumab
- A Study of Nemolizumab for the Treatment of Adults With Systemic SclerosisRecruitingPhase 2Galderma R&DNCT07047690Written as Nemolizumab
- Nemolizumab to Treat Lichen Planopilaris, a Noncontrolled, Prospective, Pilot Study.RecruitingPhase 4The Skin Center Dermatology GroupNCT07396168Written as Nemolizumab
- Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic DermatitisCompletedPhase 3Galderma R&DNCT03989206Written as Nemolizumab
- Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)Active, not recruitingPhase 2Galderma R&DNCT07074977Written as nemolizumab
- Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic DermatitisCompletedPhase 2Galderma R&DNCT04921345Written as Nemolizumab
- A Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With NemolizumabCompletedPhase 2Galderma R&DNCT04365387Written as Nemolizumab
- To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe PruritusCompletedPhase 2/3Galderma R&DNCT05075408Written as Nemolizumab
- An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic SclerosisCompletedPhase 2Maruho Co., Ltd.NCT05214794Written as nemolizumab
- A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)Active, not recruitingPhase 3Galderma R&DNCT04204616Written as Nemolizumab
- Study to Access the Relative Bioavailability of Subcutaneous Dose of Nemolizumab When Administered Via Auto-Injector Versus Dual-Chamber SyringeCompletedPhase 1Galderma R&DNCT05405985Written as Nemolizumab
- A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic DermatitisCompletedPhase 2Galderma R&DNCT04562116Written as Nemolizumab
- A Study to Evaluate the Durability of Response and Safety of Nemolizumab for 24 Weeks in Participants With Prurigo NodularisCompletedPhase 3Galderma R&DNCT05052983Written as Nemolizumab
- Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic DermatitisCompletedPhase 3Galderma R&DNCT03985943Written as Nemolizumab
- Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic DermatitisCompletedPhase 3Galderma R&DNCT03989349Written as Nemolizumab
- Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)CompletedPhase 3Galderma R&DNCT04501666Written as Nemolizumab 30 mg
Codes
What other systems call nemolizumab · ClinicalTrials.gg INT000569
- MeSH (NLM) C000612881nemolizumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) GN465U8B72NEMOLIZUMABConfirmed FDA, NLM
- NCI Thesaurus C170211NemolizumabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000612881 | nemolizumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | GN465U8B72 | NEMOLIZUMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C170211 | Nemolizumab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.